Our top pick for
TransMedics Group, Inc is a medical devices business based in the US. TransMedics Group shares (TMDX) are listed on the NASDAQ and all prices are listed in US Dollars. TransMedics Group employs 110 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$11.64 - $49.50|
|50-day moving average||$36.26|
|200-day moving average||$23.49|
|Wall St. target price||$56.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.76|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$25.6 million|
|Gross profit TTM||$16.6 million|
|Return on assets TTM||-12.82%|
|Return on equity TTM||-36.27%|
|Market capitalisation||$753.4 million|
TTM: trailing 12 months
There are currently 973,272 TransMedics Group shares held short by investors – that's known as TransMedics Group's "short interest". This figure is 30.8% up from 744,355 last month.
There are a few different ways that this level of interest in shorting TransMedics Group shares can be evaluated.
TransMedics Group's "short interest ratio" (SIR) is the quantity of TransMedics Group shares currently shorted divided by the average quantity of TransMedics Group shares traded daily (recently around 868992.85714286). TransMedics Group's SIR currently stands at 1.12. In other words for every 100,000 TransMedics Group shares traded daily on the market, roughly 1120 shares are currently held short.
However TransMedics Group's short interest can also be evaluated against the total number of TransMedics Group shares, or, against the total number of tradable TransMedics Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TransMedics Group's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 TransMedics Group shares in existence, roughly 40 shares are currently held short) or 0.0514% of the tradable shares (for every 100,000 tradable TransMedics Group shares, roughly 51 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against TransMedics Group.
Find out more about how you can short TransMedics Group stock.
We're not expecting TransMedics Group to pay a dividend over the next 12 months.
TransMedics Group, Inc. , a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts. .
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.